Reuters logo
BRIEF-Bayer says phase III compass study shows efficacy of Xarelto
February 10, 2017 / 5:46 PM / 9 months ago

BRIEF-Bayer says phase III compass study shows efficacy of Xarelto

Feb 10 (Reuters) - Bayer AG :

* Bayer announces phase III compass study1 shows efficacy of Xarelto (rivaroxaban) for the prevention of major adverse cardiac events in patients with coronary or peripheral artery disease and meets primary endpoint early

* Bayer -following planned interim analysis, DMC recommended to stop trial early as primary mace endpoint reached its prespecified criteria for superiority Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below